Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing therapies for neurodegenerative and metabolic disorders, was featured on the BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, which targets mobility loss in multiple sclerosis (MS) by addressing nerve damage, an area he believes remains unmet by current treatments.
Durkacz also highlighted the company's commercial product, unbuzzd(TM), an over-the-counter alcohol metabolism supplement designed to accelerate blood alcohol clearance. The product is currently available in the U.S. market, and Quantum retains a 19.84% stake in Unbuzzd Wellness Inc., along with royalty payments: 7% of sales until $250 million is reached, then 3% in perpetuity. This structure provides a recurring revenue stream without diluting Quantum's focus on its pharmaceutical pipeline.
The most significant upcoming milestone is the Phase 2 clinical trial for Lucid-MS, which will be the first study evaluating the drug candidate in MS patients, following Phase 1 testing in healthy volunteers. Success in this trial could position Lucid-MS as a first-in-class therapy for myelin repair, a critical unmet need in MS treatment. The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., holds the patent for this new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
Quantum's broader strategy involves building a portfolio of innovative assets. Beyond Lucid-MS and unbuzzd, the company retains 100% rights to develop similar products for pharmaceutical and medical uses. The podcast appearance underscores the company's commitment to communicating its progress to investors and stakeholders.
For more details, the full press release is available at https://ibn.fm/8sLvp. Investors can find the latest news and updates on QNTM at the company's newsroom: https://ibn.fm/QNTM.
